Phenotype heterogeneity of immune checkpoint inhibitor–chemotherapy reporting across small-cell and non-small-cell lung cancer: a dual-database FAERS–JADER pharmacovigilance study

Background Immune checkpoint inhibitors (ICIs) are used with different chemotherapy backbones in small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). We examined whether adverse-event reporting-category composition differed across histology–drug co-reporting contexts in two spontaneous-reporting databases. Methods We analyzed deduplicated reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS; through 2026 Q2) and Japanese Adverse Drug Event Report database (JADER; July 2026 release). Eligibility required lung-cancer indications, compatible histology, and specified suspect-drug roles for an ICI and chemotherapy components. Co-reported drugs defined SCLC platinum–etoposide (EP), NSCLC pemetrexed–platinum (PP), and NSCLC paclitaxel–platinum (PC) contexts without confirming concurrent administration. MedDRA version 29.0 Preferred Term dictionaries defined bone-marrow (BM), infection (INF), and lung-injury (LUNG) modules and five mutually exclusive reporting categories. Multinomial relative risk ratios (RRRs) compared each category with unmapped reports (UNC), using EP as the exposure reference. FAERS maximum-likelihood estimates and exploratory JADER Firth estimates were analyzed separately; Benjamini–Hochberg correction covered six primary comparisons per database. A separate 1,111-report subset underwent human review. Results The full analytic cohort contained 11,111 reports: 6,445 from FAERS and 4,666 from JADER. BM-only represented 36.3%, 22.3%, and 27.7% of FAERS EP, PP, and PC reports, respectively, and 46.5%, 10.9%, and 24.2% of JADER reports. PP-versus-EP BM-only RRRs were 0.46 (95% confidence interval 0.38–0.56) in FAERS and 0.29 (0.22–0.38) in JADER; PC-versus-EP estimates were 0.59 (0.50–0.70) and 0.50 (0.40–0.61), respectively (all q<0.001). Within NSCLC, PP-versus-PC RRRs were 0.77 (0.65–0.91) and 0.65 (0.51–0.82), but stricter nonsquamous common-support estimates were imprecise and did not pass multiplicity correction. Infection and lung-only results lacked consistent adjusted concordance. Human review assessed report coding and supplied adjudicated phenotype labels without an independent clinical reference standard. Conclusions BM-only reporting composition differed across the three co-reporting contexts, with directional concordance between databases. Structural coupling of histology and chemotherapy, uncertain concurrent exposure, and reporting bias prevent attribution to individual drugs. These findings generate hypotheses about reporting patterns; they do not estimate clinical incidence, absolute toxicity risk, or causal treatment effects.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-18
DOI
https://doi.org/10.3389/fimmu.2026.2021453
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Phenotype heterogeneity of immune checkpoint inhibitor–chemotherapy reporting across small-cell and non-small-cell lung cancer: a dual-database FAERS–JADER pharmacovigilance study

Jiehuan Lin, Canxing Wu, Danhong Xiong, Hongjin Wang
5 links
Frontiers in Immunology
Pharmacovigilance and Adverse Drug Reactions
article

Phenotype heterogeneity of immune checkpoint inhibitor–chemotherapy reporting across small-cell and non-small-cell lung cancer: a dual-database FAERS–JADER pharmacovigilance study

Jiehuan Lin, Canxing Wu, Danhong Xiong, Hongjin Wang
article en

Abstract

Background Immune checkpoint inhibitors (ICIs) are used with different chemotherapy backbones in small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). We examined whether adverse-event reporting-category composition differed across histology–drug co-reporting contexts in two spontaneous-reporting databases. Methods We analyzed deduplicated reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS; through 2026 Q2) and Japanese Adverse Drug Event Report database (JADER; July 2026 release). Eligibility required lung-cancer indications, compatible histology, and specified suspect-drug roles for an ICI and chemotherapy components. Co-reported drugs defined SCLC platinum–etoposide (EP), NSCLC pemetrexed–platinum (PP), and NSCLC paclitaxel–platinum (PC) contexts without confirming concurrent administration. MedDRA version 29.0 Preferred Term dictionaries defined bone-marrow (BM), infection (INF), and lung-injury (LUNG) modules and five mutually exclusive reporting categories. Multinomial relative risk ratios (RRRs) compared each category with unmapped reports (UNC), using EP as the exposure reference. FAERS maximum-likelihood estimates and exploratory JADER Firth estimates were analyzed separately; Benjamini–Hochberg correction covered six primary comparisons per database. A separate 1,111-report subset underwent human review. Results The full analytic cohort contained 11,111 reports: 6,445 from FAERS and 4,666 from JADER. BM-only represented 36.3%, 22.3%, and 27.7% of FAERS EP, PP, and PC reports, respectively, and 46.5%, 10.9%, and 24.2% of JADER reports. PP-versus-EP BM-only RRRs were 0.46 (95% confidence interval 0.38–0.56) in FAERS and 0.29 (0.22–0.38) in JADER; PC-versus-EP estimates were 0.59 (0.50–0.70) and 0.50 (0.40–0.61), respectively (all q<0.001). Within NSCLC, PP-versus-PC RRRs were 0.77 (0.65–0.91) and 0.65 (0.51–0.82), but stricter nonsquamous common-support estimates were imprecise and did not pass multiplicity correction. Infection and lung-only results lacked consistent adjusted concordance. Human review assessed report coding and supplied adjudicated phenotype labels without an independent clinical reference standard. Conclusions BM-only reporting composition differed across the three co-reporting contexts, with directional concordance between databases. Structural coupling of histology and chemotherapy, uncertain concurrent exposure, and reporting bias prevent attribution to individual drugs. These findings generate hypotheses about reporting patterns; they do not estimate clinical incidence, absolute toxicity risk, or causal treatment effects.

Frontiers in ImmunologyVol. 17
Fujian Medical University (CN), Longyan University (CN), First Affiliated Hospital of Fujian Medical University (CN)
Good health and well-being
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon